Contrarius Investment Management released its Q3 investor letter for the “Contrarius Global Equity Fund”, reporting a 30.9% return for the investor class, outperforming the MSCI World Index and Average Global Equity Fund. The fund’s investment philosophy deviates from the benchmark World Index, with top holdings like Intellia Therapeutics, Inc. (NASDAQ:NTLA).

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage gene editing company highlighted in Contrarius Global Equity Fund’s Q3 2025 investor letter. The stock had a one-month return of 12.84% and closed at $9.14 per share on December 29, 2025, with a market cap of $1.059 billion. The treatment process for Intellia Therapeutics, Inc. (NTLA) involves stem cell extraction, editing, chemotherapy, and recovery, with intense side effects.

In Q3 2025, Intellia Therapeutics, Inc. (NASDAQ:NTLA) reported a net loss of $101.3 million, down from the prior year quarter. While 31 hedge fund portfolios held NTLA, Contrarius Global Equity Fund believes other AI stocks offer greater upside potential with less downside risk. The fund does not list NTLA among the 30 most popular stocks among hedge funds.

In another article, Intellia Therapeutics, Inc. (NASDAQ:NTLA) was mentioned as an oversold biotech stock to invest in. For more hedge fund investor letters from Q3 2025, visit the hedge fund investor letters page. Check out the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money. No disclosures.

Read more at Yahoo Finance: What Makes Intellia Therapeutics (NTLA) an Interesting Investment?